- Home
- PMM vs ATAI Comparison
PMM vs ATAI Comparison
Compare PMM & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMM | ATAI |
|---|---|---|
| Founded | 1989 | 2018 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.4M | 1.4B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PMM | ATAI |
|---|---|---|
| Price | $6.22 | $4.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | 118.3K | ★ 3.2M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | ★ $3,018,000.00 |
| Revenue This Year | N/A | $943.18 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.52 | ★ N/A |
| Revenue Growth | N/A | ★ 811.78 |
| 52 Week Low | $5.00 | $1.15 |
| 52 Week High | $6.42 | $6.75 |
Technical Indicators
Market Signals| Indicator | PMM | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 58.11 | 47.85 |
| Support Level | $6.10 | $3.88 |
| Resistance Level | $6.21 | $4.72 |
| Average True Range (ATR) | 0.08 | 0.25 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 51.72 | 35.71 |
Price Performance
Historical ComparisonAbout PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.